

March 6, 2024

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
**The Manager – Listing,**  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Ref: Scrip Code: 543322**

**Ref: Scrip Name: GLS**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our letter dated September 21, 2023 in relation to the share purchase agreement dated September 21, 2023 (“Share Purchase Agreement”) among the Company, Glenmark Pharmaceuticals Limited (“GPL”) and Nirma Limited (“Nirma”) for the sale of 91,895,379 equity shares (“Sale Shares”) representing 75% of the current issued and paid-up equity share capital of the Company, by GPL to Nirma Limited. Closing under the Share Purchase Agreement has been initiated and will be completed upon the completion of the receipt of the Sale Shares by Nirma from GPL.

This is for your information and records.

**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary and Compliance Officer**